Cargando…

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G

Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received b...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hiroya, Yamanaka, Takeharu, Sakai, Daisuke, Muro, Kei, Yamazaki, Kentaro, Nakata, Susumu, Kimura, Hiroyuki, Ruff, Paul, Kim, Tae Won, Peeters, Marc, Price, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/
https://www.ncbi.nlm.nih.gov/pubmed/32605298
http://dx.doi.org/10.3390/cancers12071715
_version_ 1783567592215019520
author Taniguchi, Hiroya
Yamanaka, Takeharu
Sakai, Daisuke
Muro, Kei
Yamazaki, Kentaro
Nakata, Susumu
Kimura, Hiroyuki
Ruff, Paul
Kim, Tae Won
Peeters, Marc
Price, Timothy
author_facet Taniguchi, Hiroya
Yamanaka, Takeharu
Sakai, Daisuke
Muro, Kei
Yamazaki, Kentaro
Nakata, Susumu
Kimura, Hiroyuki
Ruff, Paul
Kim, Tae Won
Peeters, Marc
Price, Timothy
author_sort Taniguchi, Hiroya
collection PubMed
description Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics. Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58–0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64–0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54–0.87; p = 0.0013). Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643).
format Online
Article
Text
id pubmed-7407286
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74072862020-08-11 Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G Taniguchi, Hiroya Yamanaka, Takeharu Sakai, Daisuke Muro, Kei Yamazaki, Kentaro Nakata, Susumu Kimura, Hiroyuki Ruff, Paul Kim, Tae Won Peeters, Marc Price, Timothy Cancers (Basel) Article Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics. Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58–0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64–0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54–0.87; p = 0.0013). Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643). MDPI 2020-06-28 /pmc/articles/PMC7407286/ /pubmed/32605298 http://dx.doi.org/10.3390/cancers12071715 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Taniguchi, Hiroya
Yamanaka, Takeharu
Sakai, Daisuke
Muro, Kei
Yamazaki, Kentaro
Nakata, Susumu
Kimura, Hiroyuki
Ruff, Paul
Kim, Tae Won
Peeters, Marc
Price, Timothy
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title_full Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title_fullStr Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title_full_unstemmed Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title_short Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
title_sort efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab; a combined analysis of individual patient data from aspecct and wjog6510g
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/
https://www.ncbi.nlm.nih.gov/pubmed/32605298
http://dx.doi.org/10.3390/cancers12071715
work_keys_str_mv AT taniguchihiroya efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT yamanakatakeharu efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT sakaidaisuke efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT murokei efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT yamazakikentaro efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT nakatasusumu efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT kimurahiroyuki efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT ruffpaul efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT kimtaewon efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT peetersmarc efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g
AT pricetimothy efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g